Results 101 to 110 of about 3,144,476 (264)

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]

, 2014
Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip, Kaseb, Ahmed O, Kurzrock, Razelle, Tsimberidou, Apostolia M, Wolff, Robert A   +4 more
core   +3 more sources

m6A-mediated lnc-OXAR promotes oxaliplatin resistance by enhancing Ku70 stability in non-alcoholic steatohepatitis-related hepatocellular carcinoma

Journal of experimental & clinical cancer research : CR
The escalating prevalence of metabolic diseases has led to a rapid increase in non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (NASH-HCC). While oxaliplatin (OXA)-based hepatic arterial infusion chemotherapy (HAIC) has shown promise
Zhu Lin, Zhenkun Huang, Jiliang Qiu, Yunxing Shi, Dinglan Zuo, Zhiyu Qiu, Wei He, Yi Niu, Yunfei Yuan, Binkui Li   +9 more
semanticscholar   +1 more source

Inulin‐Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy

Advanced Science, EarlyView.
Schematic representation of ZIF‐8@OXA@inulin for cancer immunotherapy. Synthesis of ZIF‐8@OXA@inulin. Augmentation of pyroptosis, regulation of gut microbiota, and inhibition of NETs formation by ZIF‐8@OXA@inulin‐mediated comprehensive strategy for antitumor immune response. ABSTRACT Despite the potential of chemoimmunotherapy against colorectal cancer
Zhenhao Li, Jiaqiang Jiang, Yuping Zhou, Xinyuan Mao, Haotian Wen, Zhian Chen, Yutong Wang, Cong Huang, Yanfeng Hu   +8 more
wiley   +1 more source

USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer

Journal of Experimental & Clinical Cancer Research
Background Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). However, oxaliplatin resistance remains a major challenge contributing to treatment failure and poor prognosis. An increased capacity for DNA damage repair
Xingwu Liu, Shaoming Zhang, Yue An, Boyang Xu, Guanyu Yan, Mingjun Sun   +5 more
doaj   +1 more source

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens

Technology in Cancer Research & Treatment, 2023
Oxaliplatin (cyclohexane-1,2-diamine; oxalate; platinum [2+]) is a third-generation chemotherapeutic drug with anticancer effects. Oxaliplatin has a role in the treatment of several cancers.
Ali Tavakoli Pirzaman MD, Manijeh Ebrahimzadeh Pirshahid MD, Bahareh Babajani MS, Amirhossein Rahmati MS, Shokat Niknezhad MS, Rezvan Hosseinzadeh MD, Mehdi Taheri MS, Faezeh Ebrahimi-Zadeh MD, Shahrbanoo Doostmohamadian MS, Sohrab Kazemi PhD   +9 more
doaj   +1 more source

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX [PDF]

, 2018
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with lack of predictive biomarkers. We conducted a study to assess DNA damage repair (DDR) gene mutations as a predictive biomarker in PDAC patients treated with FOLFIRINOX ...
Gbolahan, Olumide, Hancock, Brad A., O'Neil, Bert H., Radovich, Milan, Sehdev, Amikar, Shahda, Safi, Stanley, Melissa, Wan, Jun, Wu, Howard H.   +8 more
core   +1 more source

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer

British Journal of Cancer, 2022
Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival.
C. Hsieh, Sen-Huei Hsu, Chih-Yu Lin, H. Liaw, Ting-Wei Li, Kuan-Ying Jiang, N. Chiang, Shang-Hung Chen, B. Lin, Po-Chuan Chen, Ren-Hao Chan, P. Lin, Yu-Min Yeh, Che-Hung Shen   +13 more
semanticscholar   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

Advanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang   +12 more
wiley   +1 more source

miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity

Cellular Physiology and Biochemistry, 2018
Background/Aims: Although oxaliplatin is one of the most effective chemotherapeutic drugs used to treat colorectal cancer (CRC), long-term administration usually induces acquired drug resistance during the course of treatment.
Yongqiang Hua, Yaodong Zhu, Jijie Zhang, Zhenfeng Zhu, Zhouyu Ning, Hao Chen, Luming Liu, Zhen Chen, Zhiqiang  Meng   +8 more
doaj   +1 more source

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer [PDF]

, 2019
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease.
Belardinilli, Francesca, Bellavia, Diana, Bonfiglio, Caterina, Canettieri, Gianluca, Capalbo, Carlo, Cardinali, Beatrice, Colella, Mariarosaria, Colicchia, Valeria, Coppa, Anna, Cortesi, Enrico, Filetti, Marco, Giannini, Giuseppe, Infante, Paola, Longo, Flavia, Magri, Valentina, Malapelle, Umberto, Marchetti, Paolo, Mezi, Silvia, Milanetti, Edoardo, Nicolussi, Arianna, Paci, Paola, Pecorari, Silvia, Petroni, Marialaura, Pisapia, Pasquale, Prete, Alessandra, Raimondo, Domenico, Santoni, Matteo, Tessitore, Alessandra, Troncone, Giancarlo, Valentini, Virginia   +29 more
core   +2 more sources